Ashley Gardyne, Senior Portfolio Manager — International Shares17 April, 2019

There were two newsworthy developments for our portfolio company Edwards Lifesciences over the last month. Firstly, its breakthrough transcatheter aortic heart valve received some great clinical trial results, and secondly, Mick Jagger’s successful heart surgery provided this new technology with some well-deserved publicity.

We have held Edwards in the International Growth Fund for the last two years and it is a great example of the type of business we are looking for at Fisher Funds. It has a leading market position, a long growth runway, and management has significant skin in the game.

Read on >